Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR) - BioSpace

Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)  BioSpace

Published: May 29, 2019. Data from a sizable (n=259) open-label part of the Phase 4 study showed 62.5 percent of patients with persistently active RA achieved ...



Comments

Popular posts from this blog

Different types of doctors in South Africa and their salaries 2022 - Briefly

Your Covid booster side effects shouldn't be as 'intense' this time — here's what to expect - CNBC

Ebstein's Anomaly: Symptoms, Causes, and Treatments - Verywell Health